biotech / news / / Business Standard
Combined entity to have revenue of $12.4 billion; enters biosimilars big league.
Sun Pharma will acquire Organon for $11.75 billion in one of India's largest outbound deals.
KEY POINTS
- The combined entity will have $12.4 billion revenue, entering the top 25 global pharmaceutical firms.
- Sun Pharma becomes a top-three global player in women’s health and seventh in biosimilars.
- The acquisition establishes an innovative medicines portfolio accounting for 27% of combined revenues.
COMPANIES
Summarized by Newsio from Business Standard. How we summarize →